Oasmia Pharmaceutical AB (publ) (OASM) Competitors

GT Biopharma (NASDAQ:GTBP) and Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk.

Do institutionals and insiders hold more shares of GTBP or OASM?

8.1% of GT Biopharma shares are held by institutional investors. Comparatively, 0.1% of Oasmia Pharmaceutical AB (publ) shares are held by institutional investors. 10.9% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Is GTBP or OASM more profitable?

GT Biopharma has a net margin of 0.00% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Oasmia Pharmaceutical AB (publ)'s return on equity of -43.94% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-257.47%	-131.09%
Oasmia Pharmaceutical AB (publ)	-8,633.64%	-43.94%	-28.92%

Do analysts recommend GTBP or OASM?

GT Biopharma presently has a consensus price target of $11.00, suggesting a potential upside of 348.98%. Given GT Biopharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe GT Biopharma is more favorable than Oasmia Pharmaceutical AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Oasmia Pharmaceutical AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media favor GTBP or OASM?

In the previous week, GT Biopharma had 2 more articles in the media than Oasmia Pharmaceutical AB (publ). MarketBeat recorded 2 mentions for GT Biopharma and 0 mentions for Oasmia Pharmaceutical AB (publ). GT Biopharma's average media sentiment score of 1.45 beat Oasmia Pharmaceutical AB (publ)'s score of 0.00 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
GT Biopharma	Positive
Oasmia Pharmaceutical AB (publ)	Neutral

Which has more risk & volatility, GTBP or OASM?

GT Biopharma has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Oasmia Pharmaceutical AB (publ) has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Does the MarketBeat Community favor GTBP or OASM?

Oasmia Pharmaceutical AB (publ) received 9 more outperform votes than GT Biopharma when rated by MarketBeat users. Likewise, 65.97% of users gave Oasmia Pharmaceutical AB (publ) an outperform vote while only 63.24% of users gave GT Biopharma an outperform vote.

Company	Underperform	Outperform
GT Biopharma	Outperform Votes 117 63.24%	Underperform Votes 68 36.76%
Oasmia Pharmaceutical AB (publ)	Outperform Votes 126 65.97%	Underperform Votes 65 34.03%

Which has stronger valuation & earnings, GTBP or OASM?

GT Biopharma has higher earnings, but lower revenue than Oasmia Pharmaceutical AB (publ).

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$7.60M	-$7.00	-0.35
Oasmia Pharmaceutical AB (publ)	$220K	6.82	-$18.95M	N/A	N/A

Summary

GT Biopharma beats Oasmia Pharmaceutical AB (publ) on 11 of the 16 factors compared between the two stocks.